MISSISSAUGA, ON, Sept. 3, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has completed enrolment in its Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The Company expects the trial to be completed in late 2014 with top-line results anticipated in the first quarter of 2015.